Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

JACC: Cardiovascular Interventions

Volumn 8, Issue 13, 2015, Pages 1715-1726

  Ishibashi, Yuki ^a   Nakatani, Shimpei ^a   Sotomi, Yohei ^b   Suwannasom, Pannipa ^a,b,c   Grundeken, Maik J ^b   Garcia Garcia, Hector M ^a   Bartorelli, Antonio L ^d   Whitbourn, Robert ^e   Chevalier, Bernard ^f   Abizaid, Alexandre ^g   Ormiston, John A ^h   Rapoza, Richard J ⁱ   Veldhof, Susan ⁱ   Onuma, Yoshinobu ^a   Serruys, Patrick W ^j  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d UNIVERSITY OF MILAN   (Italy)

^e ST VINCENT S HOSPITAL   (Australia)

^f INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^g Dante Pazzanese Hospital   (Brazil)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ ABBOTT VASCULAR   (United States)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

bioresorbable scaffold; major adverse cardiac event(s); maximal lumen diameter

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMAL DIAMETER; PHYSICAL PARAMETERS; PRIORITY JOURNAL; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DEVICES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROSTHESIS DESIGN; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942690536     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.07.026     Document Type: Article

References (21)

1. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
2. P.W. Serruys, Y. Onuma, H.M. Garcia-Garcia, and et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months EuroIntervention 9 2014 1271 1284
3. Y. Onuma, D. Dudek, L. Thuesen, and et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial J Am Coll Cardiol Intv 6 2013 999 1009
4. P.W. Serruys, Y. Onuma, D. Dudek, and et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
5. P.W. Serruys, J.A. Ormiston, Y. Onuma, and et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
6. J.A. Ormiston, P.W. Serruys, E. Regar, and et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
7. A. Abizaid, J.R. Costa Jr., A.L. Bartorelli, and et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled EuroIntervention 10 2015 1396 1401
8. J. Gomez-Lara, R. Diletti, S. Brugaletta, and et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study EuroIntervention 8 2012 214 224
9. Y. Onuma, P.W. Serruys, T. Muramatsu, and et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb everolimus-eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB Cohort B trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 7 2014 1400 1411
10. R. Diletti, P.W. Serruys, V. Farooq, and et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design Am Heart J 164 2012 654 663
11. V. Farooq, J. Gomez-Lara, S. Brugaletta, and et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study Catheter Cardiovasc Interv 79 2012 880 888
12. P. Vranckx, V. Farooq, S. Garg, and et al. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting Heart 98 2012 1424 1430
13. P. Vranckx, P.P. Kint, M.A. Morel, G.A. Van Es, P.W. Serruys, and D.E. Cutlip Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: a lighthouse and as a toe in the water EuroIntervention 4 Suppl C 2008 C39 C44
14. R.J. Applegate, M.T. Sacrinty, W.C. Little, R.M. Santos, S.K. Gandhi, and M.A. Kutcher Incidence of coronary stent thrombosis based on academic research consortium definitions Am J Cardiol 102 2008 683 688
15. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
16. V. Farooq, P.W. Serruys, J.H. Heo, and et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice J Am Coll Cardiol Intv 6 2013 523 532
17. K. Tsuchida, W.J. van der Giessen, M. Patterson, and et al. In vivo validation of a novel three-dimensional quantitative coronary angiography system (CardiOp-B): comparison with a conventional two-dimensional system (CAAS II) and with special reference to optical coherence tomography EuroIntervention 3 2007 100 108
18. A. Mattesini, M. Pighi, N. Konstantinidis, and et al. Optical coherence tomography in bioabsorbable stents: mechanism of vascular response and guidance of stent implantation Minerva Cardioangiol 62 2014 71 82
19. A. Mattesini, G.G. Secco, G. Dall'Ara, and et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance J Am Coll Cardiol Intv 7 2014 741 750
20. I. Porto, L. Di Vito, F. Burzotta, and et al. Predictors of periprocedural (type IVa) myocardial infarction, as assessed by frequency-domain optical coherence tomography Circ Cardiovasc Interv 5 2012 89 96 S1-6
21. L. Hebsgaard, T.M. Nielsen, S. Tu, and et al. Co-registration of optical coherence tomography and X-ray angiography in percutaneous coronary intervention. The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) fusion study Int J Cardiol 182C 2014 272 278